|
|
In
earlier trials, Ziagen™ was
effective in reducing viral loads and increasing T-cell
counts. |
|
Objective
|
To
determine the effects of 3TC/AZT & Ziagen™
on viral loads and T-cell counts as compared to a standard
antireroviral combination of 3TC/AZT & Crixivan (Indinavir).
|
|
|
Volunteers
are assigned to one of three regimens of Ziagen™,
Crixivan (Indinavir) or placebo, in addition to 3TC
and AZT.
|
|
Inclusion
Criteria
|
- HIV-positive
male or female 18-65 y.o. or older
- No
previous antiretroviral therapy
- T-cell
count greater than 100
- Viral
load greater than 10,000 copies/mL
|
|
Status
__
|
Enrollment completed; study ongoing
--
|
|
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS Research Alliance
Institutional Review Board in January, 2001.
|
